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license (http://creativeAlzheimer’s disease (AD) often overlap.We examined whether plasma lipids differed among individ-
uals with autopsy-confirmed Lewy Body pathology or AD pathology.
Methods: We identified four groups with available plasma 2 years before death: high (n 5 12) and
intermediate-likelihood DLB (n 5 14) based on the third report of the DLB consortium; dementia
with Alzheimer’s pathology (AD; n 5 18); and cognitively normal with normal aging pathology
(n 5 21). Lipids were measured using ESI/MS/MS.
Results: There were overall group differences in plasma ceramides C16:0, C18:1, C20:0, and C24:1
and monohexosylceramides C18:1 and C24:1. These lipids did not differ between the high-likelihood
DLB and AD groups, but both groups had higher levels than normals. Plasma fatty acid levels did not
differ by group.
Discussion: Plasma ceramides and monohexosylceramides are elevated in people with dementia
with either high-likelihood DLB or AD pathology.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Alzheimer’s disease; Lewy body; Autopsy; Lipids; Ceramide1. Introduction
Alzheimer’s disease (AD) dementia and dementia with
Lewy bodies (DLB) are two of the most common dementias
in the population [1]. The clinical and pathologic phenotypes
of AD and DLB are heterogeneous and often overlap [2], so
there is a critical need to identify biomarkers to aid in the dif-re no conflicts of interest.
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he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).ferential diagnosis of DLB and AD. Given the high degree of
clinical heterogeneity of DLB, the use of neuropathologi-
cally confirmed cases is essential for identifying potential
DLB-specific biomarkers.
Lipids directly affect the solubility and fluidity of cell
membranes. The homeostasis of membrane and intracellular
lipids in neuron and myelin is a key component in preventing
loss of synaptic plasticity, cell death, and ultimately, neurode-
generation [3]. In addition to structural roles, many sphingoli-
pids are also bioactive and involved in signaling pathways.
Both alpha-synuclein, the primary constituent ofLewyBodies
(LB), and amyloid-beta, the primary constituent of amyloidimer’s Association. This is an open access article under the CC BY-NC-ND
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composition and can also be modified by specific lipids [4,5].
Experimental evidence suggests that mutations in the
GBA gene coding for glucocerebrosidase, which catalyzes
the conversion of glucosylceramide (a monohexosylcera-
mide) to ceramide and glucose, cause a build-up of lyso-
somal glucosylceramide. This accumulation may promote
the oligomerization of alpha-synuclein, the decreased degra-
dation of lysosomal alpha-synuclein and ultimately subse-
quent neurodegeneration [6]. Mutations in GBA are the
most prevalent risk factor for sporadic DLB [7,8].
Furthermore, plasma ceramide and monohexosylceramide
levels were found to be elevated in sporadic, non-GBA
Parkinson’s disease patients, with the and highest levels
among cognitively impaired patients [9].
In addition to an association between specific sphingoli-
pids and DLB, several lines of evidence suggest both direct
and indirect associations between ceramides and amyloid-
beta (Ab) levels, the hallmark AD pathology [10–15].
Using a sample of clinically diagnosed cases, we found
that plasma ceramide levels predicted risk of cognitive
impairment and AD among cognitively normal individuals
[16,17], memory decline and hippocampal volume loss
among patients with amnestic mild cognitive impairment
[18], and faster rates of cognitive decline among AD patients
[19]. The primary objective of the present study was to deter-
mine whether levels of ceramides and monohexosylcera-
mides, measured at the last visit before autopsy, could be
useful blood-based biomarkers indicative of LB and/or AD
pathology. We assayed a panel of fatty acids to assess the
specificity of any findings to sphingolipids as opposed to
global lipid changes in these neurodegenerative disorders.
A secondary objective was to determine whether there was
a relationship between the plasma lipids and amyloid and
neurofibrillary tangle pathology.2. Methods
All individuals were enrolled in the Mayo Clinic Alz-
heimer’s Disease Research Center (ADRC) and donated their
brain to the Neuropathology Core. Eligibility criteria for the
proposed study included an autopsy report and available blood
at the last study visit before death. Standardized methods for
sampling and neuropathologic examination were performed
according to the third report of the DLB consortium
(CDLB) [20,21] and the Consortium to Establish a Registry
forAlzheimer’sDiseaseguidelines [22].Braak neurofibrillary
tangle (NFT) stage was determined based on the distribution
of NFTs assessed with Bielschowsky silver stain [23]. A
consensus clinical diagnosis was determined at each study
visit by a panel of neurologists, neuropsychologists, and
nurses who reviewed all patient information including neuro-
psychological results, activities of daily living, and the Clin-
ical Dementia Rating scale. The diagnosis of dementia was
based on DSM-III-R criteria [24].We identified the following
four groups: (1) Cognitively normal-normal pathology [CN,n 5 21]. These individuals had no LBs, had low-likelihood
AD according to the National Institute of Aging (NIA)-Rea-
gan Criteria [25], and were cognitively normal as of their
last study visit. (2) High-likelihood DLB [n5 13]. These in-
dividuals met criteria for high-likelihood DLB according to
the CDLB, had Braak NFT stage  IV, low to intermediate-
likelihoodAD, and a diagnosis of dementia as of the last study
visit. Twelve patients had diffuse LB and one had transitional
LB. (3) Intermediate-likelihoodDLB (n5 17). These individ-
uals had both DLB andAD pathologies. They had transitional
(n5 14) or diffuse (n5 3) LBs, met criteria for intermediate-
likelihood DLB according to the CDLB, had Braak NFT
stage  IV, intermediate to high-likelihood AD, and a diag-
nosis of dementia as of the last study visit. (4)Alzheimer’s dis-
ease pathology (AD, n 5 18). These individuals had high
(n 5 16) or intermediate (n 5 2) likelihood AD according
to NIA-Reagan criteria, had Braak NFT stage  IV, no LBs,
and had a diagnosis of probable AD dementia. Given our pre-
vious report that plasma ceramides increase with age and are
higher in women [26], we frequency matched the four groups
by sex and also by age.
2.1. Blood collection procedures
All blood samples in theMayo Clinic ADRC are collected
from nonfasting participants in the sitting position in a clin-
ical laboratory. Serum tubes (red-top) are drawn first, fol-
lowed by EDTA plasma tubes. Blood is drawn from the
median cubital vein with a 21 g needle and typically centri-
fuged at 2000 g for 10 minutes at 4C. The serum and plasma
are aliquoted into 0.5 mL and stored in a280C freezer until
use. None of the aliquots were thawed before being pulled to
measure the sphingolipids and fatty acids. We have previ-
ously shown that long-term storage, up to 38 years, in long-
term280C freezers does not affect sphingolipid levels [26].
2.2. Assay methodology
The targeted sphingolipid and fatty acid analyses were
conducted by the Mayo Clinic Metabolomics Core. Electro-
spray ionization mass spectrometry was used to quantify
plasma ceramides, sphinganine, sphingosine, sphingosine-
1-phosphate (S1P), monohexosylceramides, and free fatty
acids. The lipids were extracted from 200 mL of plasma after
the addition of internal standards. The extracts were
measured against a standard curve on the Thermo TSQ
Quantum Ultra mass spectrometer (West Palm Beach, FL)
coupled with a Waters Acquity UPLC system (Milford,
MA) and quantified in mM units.
2.3. Statistical analyses
Our primary analyses focused on identifying group dif-
ferences in the demographic and clinical variables and in
plasma lipids using Kruskal–Wallis rank tests. In subsequent
analyses, we also examined the association between the
plasma lipids and NIA-Reagan Criteria and Braak NFT
Table 1
Demographics and clinical characteristics by autopsy-confirmed pathology group
Demographics
CN (N 5 21)
High-likelihood
DLB (N 5 13)
Intermediate-likelihood
DLB (N 5 17) AD (N 5 18)
X2
4-group
Comparison
P valueMedian (IQR)/N (%) Median (IQR)/N (%) Median (IQR)/N (%) Median (IQR)/N (%)
Age at blood draw 81.0 (77.0, 86.0) 75.5 (73.5, 80.5) 80.0 (73.0, 86.0) 78.0 (75.0, 84.0) 4.82 .185
Age at death 82.0 (79.0, 90.0) 78.5 (75.5, 81.5) 82.0 (74, 88.0) 82.0 (78.0, 86.0) 4.07 .254
Men 16 (76.2%) 10 (83.3%) 13 (76.5%) 13 (72.2%) 0.50 .920
CDR–final score 0.0 (0.0, 0.0) 1.0 (1.0, 1.0)* 2.0 (1.0, 2.0)*y 2.0 (1.0, 2.0)*z 46.67 ,.0001
MMSE 29.0 (28.0, 29.0) 19.0 (18.0, 21.0)* 15.0 (12.0, 18.0)*y 14.0 (9.0, 17.0)*y 22.87 ,.0001
Abbreviations: CN, cognitively normal with normal aging pathology; IQR, interquartile range; DLB, dementia with Lewy bodies; AD, dementia with Alz-
heimer’s disease pathology; CDR, Clinical Dementia Rating Scale; MMSE, Mini-Mental State Examination.
*P , .01 versus CN.
yP , .05 versus high likelihood DLB.
zP , .01 versus high likelihood DLB.
R. Savica et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 3 (2016) 43-50 45stage. A P value ,.05 was considered statistically signifi-
cant. All analyses were performed using Stata, version
12.1 (StataCorp LP, College Station, TX).
3. Results
3.1. Demographic and clinical characteristics
The median (interquartile range) for the time between age
of the blood draw and age at death was 2.0 (1.0, 3.0) years and
did not differ by group. The demographic and clinical charac-
teristics of the groups are shown in Table 1. Among the three
pathologic groups with dementia, the intermediate-likelihood
DLB and AD groups had higher Clinical Dementia Rating
scores and lower mini-mental state examination scores at
the last ADRC clinical visit before death compared to the
high-likelihood DLB and CN groups.Table 2
Plasma sphingolipid levels by autopsy-confirmed pathology group
Plasma sphingolipid
CN (N 5 21)
High likelihood
DLB (N 5 13)
Int
DL
Median (IQR)/N (%) Median (IQR)/N (%) Me
Sphingosine 0.008 (0.004, 0.011) 0.006 (0.005, 0.009) 0.0
Sphinganine 0.007 (0.004, 0.011) 0.004 (0.004, 0.007) 0.0
S1P 2.04 (1.17, 3.34) 2.04 (1.77, 2.28) 3.
Ceramides
16:0 0.47 (0.38, 0.52) 0.603 (0.50, 0.66)*y 0.
18:1 0.02 (0.02, 0.03) 0.033 (0.02, 0.04)*y 0.
18:0 0.08 (0.06, 0.10) 0.13 (0.08, 0.15) 0.
20:0 0.17 (0.13, 0.21) 0.24 (0.17, 0.27)zy 0.
24:1 0.80 (0.70, 0.96) 1.06 (0.78, 1.36)zy 0.
24:0 2.34 (1.97, 2.61) 2.33 (1.41, 2.64) 1.
Monohexosylceramides
18:0 0.18 (0.11, 0.26) 0.23 (0.19, 0.32) 0.
18:1 0.01 (0.01, 0.02) 0.02 (0.02, 0.04)*y 0.
24:1 0.65 (0.48, 0.77) 0.89 (0.78, 1.07)*y 0.
Abbreviations: CN, cognitively normal with normal aging pathology; IQR, inter
heimer’s disease pathology; S1P, Sphingosine-1-Phosphate.
*P , .01 versus CN.
yP , .05 versus intermediate-likelihood DLB.
zP , .05 versus CN.
xP , .001 versus intermediate-likelihood DLB.We first determined whether there were overall group
differences in any of the lipid levels (Table 2). There
were significant overall group differences in plasma levels
of ceramides C16:0 (X2 5 11.18, P 5 .011), C18:1
(X2 5 12.31, P 5 .006), C20:0 (X2 5 12.74, P 5 .005),
and C24:1 (X2 5 11.18, P 5 .011) and of monohexosylcer-
amides C18:1 (X2 5 14.08, P 5 .003) and C24:1
(X2 5 13.12, P 5 .004). Examining two-way comparisons,
both the high-likelihood DLB and the AD groups had
significantly elevated levels of these lipids compared to
the CN group (Table 2 and Fig. 1). These lipid levels did
not differ between the high-likelihood DLB and AD
groups. The intermediate-likelihood DLB group had lower
ceramide and monohexosylceramide levels compared to
the high-likelihood DLB and AD groups. In fact, levels
of the intermediate-likelihood DLB group were similar toermediate-likelihood
B (N 5 17) AD (N 5 18)
X2
4-group
Comparison
P valuedian (IQR)/N (%) Median (IQR)/N (%)
09 (0.006, 0.011) 0.007 (0.004, 0.011) 1.49 .686
07 (0.005, 0.008) 0.006 (0.005, 0.008) 3.39 .335
01 (2.03, 3.92) 2.15 (1.45, 2.92) 4.95 .175
49 (0.44, 0.57) 0.57 (0.49, 0.63)z 11.18 .011
03 (0.02, 0.03) 0.03 (0.02, 0.04)* 12.31 .006
11 (0.06, 0.12) 0.11 (0.09, 0.15) 6.70 .082
16 (0.12, 0.20) 0.23 (0.18, 0.27)*x 12.74 .005
78 (0.65, 0.87) 1.06 (0.82, 1.20)zy 11.18 .011
89 (1.68, 2.26) 2.39 (1.82, 2.97) 2.92 .405
18 (0.15, 0.23) 0.22 (0.19, 0.27) 7.22 .065
01 (0.01, 0.02) 0.02 (0.02, 0.03)*y 14.08 .003
74 (0.71, 0.89) 0.82 (0.65, 0.97)z 13.12 .004
quartile range; DLB, Dementia with Lewy Bodies; AD, Dementia with Alz-
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Fig. 1. Plasma ceramides and monohexosylceramides among individuals with autopsy-confirmed Lewy body pathology or AD pathology. Standardized
methods for sampling and neuropathologic examination were performed according to the third report of the DLB consortium (CDLB) and the Consortium
to Establish a Registry for Alzheimer’s Disease guidelines. CN, Cognitively normal, normal aging pathology; DLB, Dementia with Lewy Bodies (high or in-
termediate likelihood); AD, Dementia with Alzheimer’s disease pathology. *P, .05 versus NC; **P, .01 versus NC; yP, .05 versus intermediate-likelihood
DLB; zP , .001 vs. intermediate-likelihood DLB.
R. Savica et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 3 (2016) 43-5046the CN group. There were no group differences for any of
the fatty acids (data not shown). In additional analyses, we
excluded the four individuals with transitional LBs (onehigh-likelihood DLB and three intermediate-likelihood
DLB) and the two individuals with intermediate-
likelihood AD, but the above results did not change.
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Fig. 2. Ratios of plasma sphingolipids among individuals with autopsy-confirmed Lewy Body pathology or AD pathology. Standardized methods for sampling
and neuropathologic examination were performed according to the third report of the DLB consortium (CDLB) and the Consortium to Establish a Registry for
Alzheimer’s Disease (CERAD) Guidelines. Abbreviations: S1P, sphingosine-1-phosphate; CN, Cognitively normal, normal aging pathology; DLB, Dementia
with Lewy Bodies (high or intermediate likelihood); AD, Dementia with Alzheimer’s disease pathology.
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mides to ceramides and ceramides to S1P, which is important
in determining shifts in parts of the sphingolipid pathway.
There were significant group differences in the monohexo-
sylceramide to ceramide C24:1 ratio (X2 5 10.25,
P 5 .016). This was driven by a higher ratio in the
intermediate-likelihood DLB group compared to the CN
group (1.13 vs 0.74, P 5 .017). This result indicates that
there are upregulations of both monohexosylceramide and
ceramide C24:1, but that monohexosylceramide C24:1 is
increased to a greater degree that ceramide C24:1. There
were also trends for all ceramide to S1P ratios, but only
the ceramide C20:0 to S1P ratio (X2 5 9.26, P 5 .015)
and the ceramide C24:1 to S1P ratio (X2 5 10.25,
P 5 .016) reached significance. These results were driven
by a lower ratio of ceramide to S1P in the intermediate-No
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Fig. 3. Plasma sphingosine levels by NIA Reagan criteria.likelihood DLB group compared to the high-likelihood
DLB or AD groups (Fig. 2).
Finally, in additional analyses, we determined whether
the plasma lipids were associated with NIA Reagan Criteria
or Braak NFT stage. Sphingosine was the only lipid that
differed by NIA Reagan Criteria (X2 5 11.59, P 5 .009)
with higher levels in the low-likelihood group compared to
all other groups (Fig. 3). Using Spearman correlation, there
were no associations between any of the sphingolipids and
Braak NFT stage.4. Discussion
The identification of diagnostic biomarkers to differen-
tiate between DLB and AD dementia is crucial to predict dis-
ease progression and to best determine appropriate
treatments. Previous studies suggested that specific lipids
might differentially separate these two dementias, but confir-
mation of this association requires pathological confirma-
tion. Therefore, we compared the levels of ceramides,
monohexosylceramides, and fatty acids at the last visit
before autopsy (median of 2 years) among individuals with
autopsy-confirmed LB pathology, Alzheimer pathology,
both, or neither. We found overall group differences in
plasma levels of several ceramides and monohexosylcera-
mides. The group differences were driven by significantly
higher plasma ceramide and monohexylceramide levels in
both the high-likelihood DLB and AD groups compared to
the CN group. There were no differences in any of the
plasma lipid levels between the high-likelihood DLB and
AD groups. Intriguingly, the intermediate-likelihood DLB
group had levels of ceramides and monohexosylceramides
similar to the CN group. However, when examining the ra-
tios between these two lipids, the intermediate-likelihood
DLB group had a higher monohexosylceramide to ceramide
C24:1 ratio compared to the CN group. The ceramide to S1P
ratios were also lower, some reaching significance, in the
R. Savica et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 3 (2016) 43-5048intermediate-likelihood DLB group compared to either the
high-likelihood DLB or AD groups. Notably, there were
no significant group differences in any of the fatty acids, sug-
gesting specificity to sphingolipids in relation to either DLB
or AD pathology.
GBAmutations have not been associated with risk of AD,
so we initially hypothesized that plasma monohexylcera-
mides could be higher in those with LB pathology. Further-
more, as we have previously shown that high plasma
ceramides were associated with an increased risk of AD
and rate of disease progression [16–19], we also
hypothesized that ceramides may be higher in those with
amyloid pathology. Interestingly, the results do not fit our
hypotheses. Instead, we found elevated ceramides and
monohexosylceramides in both the AD and high-
likelihood DLB groups compared to CN.We also found little
association between the sphingolipids and either NIA Rea-
gan Criteria or Braak NFT stage. Thus, these lipids are not
currently useful for the differential diagnosis of DLB. How-
ever, the mass spectrometry method we used captured mono-
hexosylceramides and did not isolate glucosylceramides
from galactosylceramides because of the technical diffi-
culties in the separation of these lipids. In future research,
we may see differences between the AD and high-
likelihood DLB groups when isolating glucosylceramides,
particularly because alpha-synuclein and glucosylceramides
(but not galactosylceramides) interact in a positive feedback
loop [6]. The measurement of glucosylsphingosine will also
be important.
Surprisingly, the levels of the ceramides and monohexo-
sylceramides in the intermediate-likelihood DLB group
were similar to the CN group. As the intermediate-
likelihood DLB group has high levels of both DLB and
AD pathology, it is not the case that the intermediate-
likelihood DLB group had less pathology. We hypothesize
that there may be a compensatory mechanisms that allows
for individuals to obtain such a large amount of pathology,
and which may be reflected in the plasma lipid levels. In sup-
port of this hypothesis, the ceramide to S1P ratios were
lower, indicating higher S1P, in the intermediate-likelihood
DLB group compared to the high likelihood or AD groups.
This is important because S1P can be anti-inflammatory
and anti-apoptotic [27]. Thus, higher levels of S1P may be
protective. Future research warrants the assessment of these
lipids in the brain in relation to the type and amount of pa-
thology.
When we examined the associations between the plasma
sphingolipids and fatty acids and either NIA Reagan criteria
or Braak NFT stage, only sphingosine was found to be sig-
nificant. We found higher levels in the low-likelihood NIA
Reagan group compared to all other groups. A direct metab-
olite of ceramides, sphingosine can be converted back to ce-
ramides or metabolized to sphingosine-1 phosphate.
Sphingosine has similar proapoptotic and proinflammatory
effects as ceramides. At this point, we are unsure what thisresult means and it could be due to chance. Additional
research and follow-up are needed.
Our study has some strengths. First, we identified and
explored the plasma lipid levels among patients with path-
ologically confirmed diagnoses of AD and/or DLB and
compared them with unaffected cognitively normal individ-
uals with normal aging pathology. Thus, we were able to di-
agnose individuals using the current pathologic gold
standard. Second, the pathologic groups were matched for
age and sex. This is important because patients with only
LB pathology are more frequently men and younger
whereas patients with only Alzheimer pathology are more
frequently women and older, and ceramides and monohex-
osylceramides increase with age and tend to be higher in
women.
Limitations of our study also warrant consideration. First,
we had a small sample of patients, but it was still a relatively
large sample for an autopsy study. Second, the collection of
blood for the present study occurred between 2001 and
2012, before the published guidelines for standardization of
preanalytic variables for blood-based biomarker studies in
AD research [28]. Blood draws in the Mayo Clinic ADRC
are standardized asmuch as possible but do not require fasting
because it has been difficult to require of elderly demented pa-
tients and some travel a long distance. Unfortunately, blood
glucose levels were also not collected at the time of the blood
draw and cannot be adjusted for. Furthermore, we do not have
information on other preanalytic processing factors thatmight
affect the results such as the type of tubes (plastic or glass), use
of rubber stoppers, confirmation of centrifugation time or
speed, or total processing time, all of which could have
changed over time. Third, plasma sphingolipids and fatty
acids could be affected by bodymass index or weight changes
due to the dementia process, as well as other comorbidities or
medication. Such information was not available for the pre-
sent analyses. Finally, as previously mentioned, we were not
able to isolate glucosylceramide nor did we have information
regarding GBA mutations.
In conclusion, our study supports previous work suggest-
ing that plasma ceramides and monohexosylceramides are
elevated in individuals with dementia and either LB or Alz-
heimer’s pathology. Interestingly, these lipids are not altered
among individuals with both pathologies. Thus, these lipids
are not currently useful for the differential diagnosis of DLB.
We hypothesize that individuals with both LB and Alz-
heimer pathology may have a compensatory mechanism
that could result in the lower lipid levels and thereby allow
for the high level of both brain pathologies. We can propose
that higher S1P levels among this group may contribute to
better compensatory mechanisms; however, additional
research is needed. Future studies need to isolate glucosyl-
ceramides and examine their relationship with alpha-
synuclein in the brain to determine the possible use of
plasma glucosylceramides as a prognostic biomarker of dis-
ease progression.
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1. Systematic review: We reviewed the literature in
PubMed that studied the association between
sphingolipids or fatty acids and dementia or brain
pathology (e.g., Lewy body, alpha-synuclein, amy-
loid-beta, neurofibrillary tangles). Studies have
examined the association between sphingolipids and
fatty acids and the clinical symptoms of Dementia
with Lewy Bodies (DLB), Parkinson’s disease, or
Alzheimer’s disease (AD). However, there were no
studies examining the associations between plasma
sphingolipids and autopsy-confirmed neuropathology.
2. Interpretation: Our study supports previous work
suggesting that plasma ceramides and monohexosyl-
ceramides are elevated in individuals with dementia
and either LB or Alzheimer’s pathology. However,
our findings suggest that neither plasma sphingoli-
pids nor plasma fatty acids can be used as diagnostic
markers for either pathology. As S1P can have anti-
apoptotic and anti-inflammatory properties, it is
possible that upregulation of this lipid could be
compensatory to allow high levels of both LB and
Alzheimer’s pathology. There were no group differ-
ences in any of the fatty acids, suggesting specificity
to sphingolipids in relation to either LB or AD pa-
thology.
3. Future directions: Future research warrants the
assessment of these lipids in the brain in relation to
the type and amount of both LB and Alzheimer’s pa-
thology. Additionally, studies are needed to isolate
plasma glucosylceramides from galactosylceramides
and to examine their relationship with brain alpha-
synuclein to determine the possible use of plasma
glucosylceramides or glucosylsphingosine as prog-
nostic biomarkers of disease progression.
References
[1] Savica R, Grossardt BR, Bower JH, Boeve BF, Ahlskog JE, RoccaWA.
Incidence of dementia with Lewy bodies and Parkinson disease de-
mentia. JAMA Neurol 2013;70:1396–402.
[2] Tsuboi Y, Dickson DW. Dementia with Lewy bodies and Parkinson’s
disease with dementia: are they different? Parkinsonism Relat Disord
2005;11(Suppl 1):S47–51.[3] MielkeMM, Lyketsos CG. Lipids and the pathogenesis of Alzheimer’s
disease: is there a link? Int Rev Psychiatry 2006;18:173–86.
[4] Ruiperez V, Darios F, Davletov B. Alpha-synuclein, lipids and Parkin-
son’s disease. Prog Lipid Res 2010;49:420–8.
[5] Eckert GP, Wood WG, Muller WE. Lipid membranes and beta-
amyloid: a harmful connection. Curr Protein Pept Sci 2010;11:319–25.
[6] Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA,
et al. Gaucher disease glucocerebrosidase and alpha-synuclein form
a bidirectional pathogenic loop in synucleinopathies. Cell 2011;
146:37–52.
[7] Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G,
Barbosa ER, et al. Multicenter analysis of glucocerebrosidase muta-
tions in Parkinson’s disease. N Engl J Med 2009;361:1651–61.
[8] Clark LN, Kartsaklis LA, Wolf Gilbert R, Dorado B, Ross BM,
Kisselev S, et al. Association of glucocerebrosidase mutations with de-
mentia with lewy bodies. Arch Neurol 2009;66:578–83.
[9] Mielke MM, Maetzler W, Haughey NJ, Bandaru VV, Savica R,
Deuschl C, et al. Plasma ceramide and glucosylceramide metabolism
is altered in sporadic Parkinson’s disease and associated with cognitive
impairment: a pilot study. PLoS One 2013;8:e73094.
[10] Lee JT, Xu J, Lee JM, Ku G, Han X, Yang DI, et al. Amyloid-beta pep-
tide induces oligodendrocyte death by activating the neutral
sphingomyelinase-ceramide pathway. J Cell Biol 2004;164:123–31.
[11] Grimm MO, Grimm HS, Patzold AJ, Zinser EG, Halonen R,
Duering M, et al. Regulation of cholesterol and sphingomyelin meta-
bolism by amyloid-beta and presenilin. Nat Cell Biol 2005;
7:1118–23.
[12] Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K,
et al. Involvement of oxidative stress-induced abnormalities in cer-
amide and cholesterol metabolism in brain aging and Alzheimer’s dis-
ease. Proc Natl Acad Sci U S A 2004;101:2070–5.
[13] Gulbins E, Kolesnick R. Raft ceramide in molecular medicine. Onco-
gene 2003;22:7070–7.
[14] Puglielli L, Ellis BC, Saunders AJ, Kovacs DM. Ceramide stabilizes
beta-site amyloid precursor protein-cleaving enzyme 1 and promotes
amyloid beta-peptide biogenesis. J Biol Chem 2003;278:19777–83.
[15] Kalvodova L, Kahya N, Schwille P, Ehehalt R, Verkade P, Drechsel D,
et al. Lipids as modulators of proteolytic activity of BACE: involve-
ment of cholesterol, glycosphingolipids, and anionic phospholipids
in vitro. J Biol Chem 2005;280:36815–23.
[16] Mielke MM, Bandaru VV, Haughey NJ, Rabins PV, Lyketsos CG,
Carlson MC. Serum sphingomyelins and ceramides are early predic-
tors of memory impairment. Neurobiol Aging 2010;31:17–24.
[17] Mielke MM, Bandaru VV, Xia J, Haughey NJ, Fried LP, Yasar S, et al.
Serum ceramides increase the risk of Alzheimer disease: the Women’s
Health and Aging Study II. Neurology 2012;79:633–41.
[18] Mielke MM, Haughey NJ, Ratnam Bandaru VV, Schech S, Carrick R,
Carlson MC, et al. Plasma ceramides are altered in mild cognitive
impairment and predict cognitive decline and hippocampal volume
loss. Alzheimers Dement 2010;6:378–85.
[19] Mielke MM, Haughey NJ, Bandaru VV, Weinberg DD, Darby E,
Zaidi N, et al. Plasma sphingomyelins are associated with cognitive
progression in Alzheimer’s disease. J Alzheimers Dis 2011;
27:259–69.
[20] McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H,
et al. Diagnosis and management of dementia with Lewy bodies: third
report of the DLB Consortium. Neurology 2005;65:1863–72.
[21] Fujishiro H, Ferman TJ, Boeve BF, Smith GE, Graff-Radford NR,
Uitti RJ, et al. Validation of the neuropathologic criteria of the third
consortium for dementia with Lewy bodies for prospectively diag-
nosed cases. J Neuropathol Exp Neurol 2008;67:649–56.
[22] Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM,
et al. The Consortium to Establish a Registry for Alzheimer’s Disease
(CERAD). Part II. Standardization of the neuropathologic assessment
of Alzheimer’s disease. Neurology 1991;41:479–86.
[23] Braak H, Braak E. Neuropathological stageing of Alzheimer-related
changes. Acta Neuropathol 1991;82:239–59.
R. Savica et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 3 (2016) 43-5050[24] American Psychiatric Association. Diagnostic and Statistical Manual
of Mental Disorders: 3rd ed. revised. Washington, DC: American
Psychiatric Association; 1987.
[25] Consensus recommendations for the postmortem diagnosis of Alz-
heimer’s disease. TheNational Institute onAging, andReagan Institute
Working Group on Diagnostic Criteria for the Neuropathological
Assessment of Alzheimer’s Disease. Neurobiol Aging 1997;18:S1–2.
[26] MielkeMM, Bandaru VV, Han D, An Y, Resnick SM, Ferrucci L, et al.
Demographic and clinical variables affecting mid- to late-lifetrajectories of plasma ceramide and dihydroceramide species. Aging
Cell 2015;14:1014–23.
[27] Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S,
et al. Suppression of ceramide-mediated programmed cell death by
sphingosine-1-phosphate. Nature 1996;381:800–3.
[28] O’Bryant SE, Gupta V, Henriksen K, Edwards M, Jeromin A, Lista S,
et al. Guidelines for the standardization of preanalytic variables for
blood-based biomarker studies in Alzheimer’s disease research. Alz-
heimers Dement 2015;11:549–60.
